Navigation Links
Presentation at the Maidstone Life Sciences "Cancer Immunotherapy: A Long-Awaited Reality"

SEATTLE, March 30, 2015 /PRNewswire/ -- TapImmune Inc. (OTCQB: TPIV), wishes to provide clarification on its participation at the Fifth Annual "Cancer Immunotherapy: A Long-Awaited Reality" conference at the New York Academy of Medicine in New York City on March 26.  TapImmune was represented at this meeting by Dr. Glynn Wilson, Chairman & CEO of TapImmune and Dr. John Bonfiglio, Strategic Advisor to the Company.  Regrettably, due to parallel meeting sessions running behind schedule, Dr. Wilson was unable to present a webcast at 4:30pm Eastern Time as originally scheduled in order to participate as an invited panellist in an important discussion on "What is the Role of Cancer Vaccines in an Environment Overwhelmed by Checkpoint Inhibitors and T Cell Immunotherapies?"  Other panellists were Dr. Robert Stein, CSO of Agenus, Inc., Dr. Reiner Laus, CEO of Annias Immunotherapeutics, Dr. Robert Pierce, CMO of OncoSec Medical, and David Berd, CMO of AVAX Technologies.  The panel discussion was moderated by Dr. Mac Cheever, MD, Fred Hutchinson Cancer Research Center, who also served as the Keynote speaker at the conference.

TapImmune regrets any inconvenience to those who wished to hear the webcast; however, the circumstances were beyond our control. The Company has put the Maidstone presentation on its website at

Dr Glynn Wilson stated, "On a most positive note, the meeting was focussed around the latest immunotherapies in development and the future of cancer treatments. It was clear from the presentations and the comments of the key opinion leaders attending the meeting that the T-cell therapies of TapImmune are currently developing fit into the combination strategies believed to be the future of treatment regimens."

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at for details. 

Forward-Looking Statement Disclaimer 
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K and other SEC filings which are available through EDGAR at The Company assumes no obligation to update the forward-looking statements.


TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO

PCG Advisory
Kirin M. Smith
Chief Operating Officer

Sean Leous
Chief Communications Officer
(646) 863-8998

J. Streicher Capital, LLC
Robert Giordano

SOURCE TapImmune Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Medivation Announce New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress
2. Tobira Therapeutics Highlights Presentations at the AASLDs Industry Colloquium for Novel Targets and Therapies in Liver Disease
3. Misonix Announces Presentation At Leading Wound Conference Confirms SonicOne O.R. More Effective at Debridement of Large Wounds
4. Delcath Announces Melphalan/HDS Poster Presentation To Be Presented At The Society Of Surgical Oncology Annual Meeting
5. Update - Changed Time for Aethlon Medical Presentation at the 27th Annual ROTH Conference
6. HeartWare Presentation At The 2015 Barclays Global Healthcare Conference To Be Webcast
7. Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th
8. HeartWare Presentation At The Raymond James 36th Annual Institutional Investors Conference To Be Webcast
9. Thoratec Announces Presentations At Investor Conferences For March 2015
10. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
11. Alexza Pharmaceuticals Announces Presentation at the 27th Annual ROTH Conference
Post Your Comments:
(Date:7/2/2020)... OCEAN SPRINGS, Miss. (PRWEB) , ... July 02, ... ... Ocean Springs, Mississippi-based wholesale pharmaceutical distributor, is pleased to announce its donation of ... Health and the Michigan Department of Health and Human Services. As extreme medical ...
(Date:6/28/2020)... TAMPA, Fla. (PRWEB) , ... June 28, 2020 ... ... to improve digestive health. New studies substantiate the effectiveness of oral-care probiotics ... and oral-care probiotics? While the science behind both is simple – utilizing ...
(Date:6/25/2020)... ... June 25, 2020 , ... BeCurious Studio ... Developers & DesignRush following the launch a recent project. BeCurious Studio, the rule ... cancer survivors. , Commissioned by MyVictory Inc , the platform delivers ...
Breaking Medicine Technology:
(Date:7/2/2020)... , ... July 02, 2020 , ... ... annual Outstanding Safety Professional of the Year Award to Eric Simmons of Temecula, ... more than 250 nominations. Simmons, who holds a master’s degree in occupational safety ...
(Date:7/2/2020)... Conn. (PRWEB) , ... July 02, 2020 , ... ... of many businesses, including dental offices for non-emergency work. In conjunction with the ... reopening guidelines for Connecticut dental practices in mid-May. , Due to safety ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... botanically-derived terpenes, has officially released its new terpene infused product line including ... for consumers to enjoy cannabis terpene profiles and flavors worldwide. , “We’ve made ...
(Date:7/1/2020)... ... 2020 , ... The Society to Improve Diagnosis in Medicine ... University of Massachusetts Medical School- Baystate and Ann Gaffey, RN, MSN, CPHRM, DFASHRM, ... Directors. Dr. Salvador and Ms. Gaffey’s service began in May and the initial ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... participation in the revision and redesignation of the ANSI/APSP/ICC-7 2013 American National Standard ... Catch Basins. PHTA is seeking member participation on the PHTA-7 Standard Writing Committee ...
Breaking Medicine News(10 mins):